Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease
Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 8428-8437
DOI: 10.1111/dom.70993 ↗At a glance
Multizentrische Studie in Diabetes, Obesity and Metabolism, published online on 2026-06-28. Written by David Lam and 14 co-authors. Institution: Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Major MEDLINE topics: Diabetic Nephropathies, Diabetes Mellitus, Type 2. 20 references. The full text is freely available in PubMed Central. Funded by: Renalytix.
Abstract (original language)
Background
KidneyIntelX is a prognostic blood test for the progression of diabetic kidney disease (DKD) within 5 years. Long‐term utility is important. Materials and Methods Adults with type 2 diabetes (T2D) and CKD (G1‐G3b) from two medical centres were assessed for the following: (1) baseline KidneyIntelX risk levels and their association with GDMT usage; (2) changes in temporal kidney and metabolic trajectories after testing; (3) probability for a kidney composite outcome of sustained eGFR decline of 40% or kidney failure by baseline KidneyIntelX risk strata; and (4) risk at 12‐month for repeat‐tested participants.
Results
2470 patients with T2D and CKD (median baseline eGFR 63 mL/min/1.73 m 2 , UACR 51 mg/g, and HbA1c 7.2%), KidneyIntelX risk was 49.9% low, 40.6% intermediate, and 9.5% high. SGLT2i usage post‐test increased to 56%, 45%, 34% in high, intermediate, low‐risk groups. SGLT2i combined with GLP‐1 increased to 32%, 25%, 17% per risk group. Improvements in eGFR slope (−4.6 to −2.6 mL/min/1.73 m 2 /year), UACR (relative decrease of 23%), and HbA1c (relative decrease of 7.6%) were greatest in the high‐risk group. Hazard ratio (HR) for DKD progression for high vs. low was 10.4 [4.4–24.8] and intermediate vs. low HR was 4.0 [2.0–8.7]. With repeat testing ( n = 1143), 29% transitioned to lower risk accompanied by biomarker reductions, specifically KIM‐1, and initiation of SGLT2i or GLP‐1 doubled odds of risk reduction.
Conclusions
KidneyIntelX was associated with targeted GDMT usage with favourable changes in kidney and metabolic clinical measures and risk trajectories, with lower risk linked to therapy initiation and reduction in biomarkers.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Barbara T Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Renalytix AI, PLC, New York, New York, USA.
ORCID profiles: David Lam, Steven G Coca, Girish N Nadkarni
Funding
- Renalytix
Cite
APA
Lam, D., Freedman, B. I., Tokita, J., Fleming, F., Suarez-Farinas, M., Bagwell, B., Kirk, J., Tapp, H., Shade, L., Vega, A., Wang, S., Sinfield, C., Coca, S. G., Nadkarni, G. N., & Donovan, M. J. (2026). Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease. Diabetes, Obesity and Metabolism, 28(9), 8428-8437. https://doi.org/10.1111/dom.70993
Vancouver
Lam D, Freedman BI, Tokita J, Fleming F, Suarez-Farinas M, Bagwell B, et al. Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease. Diabetes, Obesity and Metabolism. 2026;28(9):8428-8437. doi:10.1111/dom.70993
BibTeX
@article{Lam2026,
author = {Lam, David and Freedman, Barry I and Tokita, Joji and Fleming, Fergus and Suarez-Farinas, Mayte and Bagwell, Benjamin and Kirk, Julienne and Tapp, Hazel and Shade, Lindsay and Vega, Aida and Wang, Stephanie and Sinfield, Catherine and Coca, Steven G and Nadkarni, Girish N and Donovan, Michael J},
title = {Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {9},
pages = {8428--8437},
doi = {10.1111/dom.70993}
}
EUVIMED